Table 3 Hazard ratios (HR) and 95% confidence intervals (CIs) for shoulder tendinopathy associated with statin use in women and men.
Statin use | Age-adjusted HR (95% CI) | Multivariable-adjusteda HR (95% CI) | Age-adjusted HR (95% CI) | Multivariable-adjusteda HR (95% CI) | |
|---|---|---|---|---|---|
Women | Men | ||||
Never use | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | |
Ever use | Any | 1.23 (1.09–1.38) | 1.14 (1.01–1.28) | 1.48 (1.30–1.69) | 1.41 (1.22–1.62) |
Low dose | 1.33 (1.08–1.64) | 1.24 (1.00–1.53) | 1.80 (1.38–2.36) | 1.72 (1.31–2.26) | |
Medium dose | 1.22 (1.07–1.38) | 1.12 (0.98–1.28) | 1.43 (1.25–1.65) | 1.36 (1.18–1.58) | |
High dose | 0.95 (0.36–2.54) | 0.86 (0.32–2.30) | 1.38 (0.84–2.26) | 1.29 (0.78–2.13) | |
Simvastatin | 1.19 (1.04–1.36) | 1.10 (0.96–1.27) | 1.41 (1.21–1.65) | 1.36 (1.16–1.59) | |
Pravastatin | 1.21 (0.65–2.27) | 1.14 (0.61–2.13) | 0.70 (0.22–2.17) | 0.66 (0.21–2.05) | |
Fluvastatin | NA | NA | NA | NA | |
Atorvastatin | 1.31 (1.08–1.59) | 1.20 (0.99–1.46) | 1.53 (1.25–1.88) | 1.44 (1.17–1.78) | |
Rosuvastatin | 1.46 (0.98–2.16) | 1.33 (0.90–1.97) | 2.17 (1.53–3.07) | 2.04 (1.43–2.89) | |
Current use | Any | 1.50 (1.03–2.18) | 1.41 (0.97–2.05) | 1.50 (1.31–1.71) | 1.43 (1.24–1.65) |
0–1 years | 1.42 (1.09–1.86) | 1.32 (1.01–1.73) | 2.13 (1.66–2.73) | 2.05 (1.59–2.64) | |
1–2 years | 1.62 (1.21–2.17) | 1.51 (1.12–2.02) | 1.64 (1.21–2.22) | 1.57 (1.16–2.14) | |
2–3 years | 1.15 (0.82–1.63) | 1.06 (0.75–1.50) | 1.48 (1.08–2.04) | 1.39 (1.00–1.92) | |
>3 years | 1.28 (1.07–1.52) | 1.15 (0.96–1.38) | 1.30 (1.09–1.53) | 1.23 (1.03–1.47) | |
Former use | Any | 1.18 (0.87–1.60) | 1.09 (0.80–1.49) | 1.27 (0.88–1.83) | 1.19 (0.83–1.72) |
<1 year ago | 1.02 (0.59–1.77) | 0.97 (0.56–1.68) | 0.99 (0.53–1.86) | 0.93 (0.50–1.74) | |
1–2 years ago | 1.44 (0.85–2.46) | 1.37 (0.81–2.34) | 0.84 (0.37–1.87) | 0.79 (0.35–1.77) | |
>2 years ago | 0.99 (0.62–1.58) | 0.94 (0.59–1.51) | 1.29 (0.78–2.12) | 1.22 (0.74–2.02) | |
